BioSpace News Archive

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the pricing of its upsized initial public offering of 8,202,565 shares of its common stock at a public offering price of $19.00 per share, f

BC Platforms and Kaiser Permanente today announced they are winners of the 2020 Microsoft Health Innovation Award in the Reimagine Health Category for enabling a unique way of pairing clinical and genomic data on the same platform to advance precision medicine capabilities.

International Isotopes Inc. (OTCQB: INIS) (the “Company”) is pleased to announce its financial results for the three months ended March 31, 2020.

Professional baseball icon, Jose Offerman, recently reflected on his bout with prostate cancer he battled last year. Offerman, former player for the LA Dodgers, Kansas City Royals, Boston Red Sox, and the New York Mets was diagnosed in August of 2019 and underwent robotic prostate cancer surgery with Dr. David Samadi

The use of e-cigarettes, vapes and mods have increased as smokers liken these alternatives as healthier and not having the same side effects of traditional cigarettes. Because e-cigarettes are readily available over the internet, unlike the sale of cigarettes, it perpetuates the notion that these are a safer alternative.

In virtual meetings with lawmakers and on Twitter tomorrow, physician and health professional leaders from the American College of Rheumatology (ACR) are sounding the alarm about the economic impact of COVID-19 on rheumatology practices and the urgent need for more targeted relief that will help specialty practices remain solvent and continue to serve patients.

Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19, and the other to treat severely ill COVID-19 patients.

Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate

Globally, thousands of scientists are working tirelessly on COVID-19 mitigation efforts, including the search for new treatments and a vaccine

Following the launch in April 2020 of Labs@Home in response to the COVID-19 pandemic began impacting transplant patient care and the world, Transplant Genomics, Inc. (“TGI”), announce today the successful growth of TruGraf® driven by adoption of Labs@Home.